glp 1 drugs and fatty liver Why are GLP-1 agonists being used to treat patients with nonalcoholic disease? Therapeutic Effects of Glucagon-like Peptide-1
Description
Reuben K
Defining inflammatory cell States in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry
95% CI, 0.67-2.17)
The relative risks of complications, including progression of CKD to end-stage kidney disease (ESKD), CVD and mortality, are increased with both reduced eGFR and elevated UACR levels [1]
Note: DTC = Direct-to-consumer
Cortes-Maisonet, G
